Literature DB >> 15698828

Bone marrow cell transplantation in clinical perspective.

Husnain Kh Haider1, Muhammad Ashraf.   

Abstract

The deficit in left ventricular performance in an ischemically damaged heart is characterized by depletion of functioning cardiomyocytes. The problem is accentuated by the inadequate intrinsic repair mechanism of the heart. Recent progress in regenerative medicine has paved way for an outside intervention to support the limited on-going reparative process in the heart through transplantation of cells with myogenic and/or angiogenic potential. The functional plasticity of bone marrow derived stem cells has been exploited for cardiac repair. The early experiences in proof-of-concept animal studies and phase-1 clinical trials have been encouraging and suggest the safety, feasibility and potential of this approach. We critically review the literature in depth to elucidate the progress in this field together with discussion of the problems and controversies that need to be addressed in order to fully exploit the potential of bone marrow stem cell transplantation with clinical relevance.

Mesh:

Year:  2005        PMID: 15698828     DOI: 10.1016/j.yjmcc.2004.12.005

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  14 in total

Review 1.  Stem cells in the infarcted heart.

Authors:  Dinender K Singla
Journal:  J Cardiovasc Transl Res       Date:  2009-11-20       Impact factor: 4.132

2.  Factors Released from Embryonic Stem Cells Stimulate c-kit-FLK-1(+ve) Progenitor Cells and Enhance Neovascularization.

Authors:  Sumbul Fatma; Donald E Selby; Reetu D Singla; Dinender K Singla
Journal:  Antioxid Redox Signal       Date:  2010-07-28       Impact factor: 8.401

3.  VEGF is critical for stem cell-mediated cardioprotection and a crucial paracrine factor for defining the age threshold in adult and neonatal stem cell function.

Authors:  Troy A Markel; Yue Wang; Jeremy L Herrmann; Paul R Crisostomo; Meijing Wang; Nathan M Novotny; Christine M Herring; Jiangning Tan; Tim Lahm; Daniel R Meldrum
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-10-10       Impact factor: 4.733

4.  Are neonatal stem cells as effective as adult stem cells in providing ischemic protection?

Authors:  Troy A Markel; Paul R Crisostomo; Maiuxi C Manukyan; Dalia Al-Azzawi; Christine M Herring; Tim Lahm; Nathan M Novotny; Daniel R Meldrum
Journal:  J Surg Res       Date:  2008-04-28       Impact factor: 2.192

5.  Embryonic stem cells improve cardiac function in Doxorubicin-induced cardiomyopathy mediated through multiple mechanisms.

Authors:  Dinender K Singla; Aisha Ahmed; Reetu Singla; Binbin Yan
Journal:  Cell Transplant       Date:  2012-03-22       Impact factor: 4.064

6.  Gender differences in injury induced mesenchymal stem cell apoptosis and VEGF, TNF, IL-6 expression: role of the 55 kDa TNF receptor (TNFR1).

Authors:  Paul R Crisostomo; Meijing Wang; Christine M Herring; Troy A Markel; Kirstan K Meldrum; Keith D Lillemoe; Daniel R Meldrum
Journal:  J Mol Cell Cardiol       Date:  2006-10-30       Impact factor: 5.000

Review 7.  Strategies to promote donor cell survival: combining preconditioning approach with stem cell transplantation.

Authors:  Husnain Kh Haider; Muhammad Ashraf
Journal:  J Mol Cell Cardiol       Date:  2008-05-10       Impact factor: 5.000

Review 8.  Role of heat shock proteins in stem cell behavior.

Authors:  Guo-Chang Fan
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

9.  TNFR1 signaling resistance associated with female stem cell cytokine production is independent of TNFR2-mediated pathways.

Authors:  Troy A Markel; Paul R Crisostomo; Meijing Wang; Yue Wang; Tim Lahm; Nathan M Novotny; Jiangning Tan; Daniel R Meldrum
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-08-06       Impact factor: 3.619

Review 10.  Embryonic stem cells in cardiac repair and regeneration.

Authors:  Dinender K Singla
Journal:  Antioxid Redox Signal       Date:  2009-08       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.